The U.S. Army has developed SpFN, a more powerful pan-coronavirus vaccine

Scientists from WRAIR's Emerging Infectious Diseases Division (EIDB) developed SpFN nanoparticle vaccines based on the ferritin platform as part of a forward-thinking "pan-SARS" strategy, which aims to solve the current epidemic and serve as a possible future The emergence of mutant strains and similar viruses is the first line of defense

"In the past 20 years, the accelerated emergence of human coronaviruses and the rise of SARS-CoV-2 variants, including the most recent Omicron (Omicron), have highlighted the continued demand for the next generation of pre-emptive vaccines that can Provide extensive protection against coronavirus diseases

A pre-clinical study published today in the journal Science Translational Medicine showed that SpFN vaccine protects non-human primates from the disease caused by the original strain of SARS-CoV-2 and induces the main SARS- Strong and broadly neutralizing antibody response of CoV-2 variant strains (including SARS-CoV-1 virus) 2002.

In April 2021, SpFN entered the first phase of human trials

Modjarrad said: "This vaccine stands out

WRAIR has developed a secondary candidate vaccine, the SARS-CoV-2 Spike Receptor Binding Domain Ferritin Nanoparticle (RFN) vaccine, which targets the coronavirus spike protein smaller than the SpFN vaccine

"The RFN vaccine candidate is more compact and has some natural advantages.

Dr.

The SpFN vaccine is a protein subunit nanoparticle vaccine platform, which means that it presents viral fragments to the immune system and triggers a protective response

The SpFN vaccine is formulated with an adjuvant called ALFQ, one of the Army liposome adjuvant family developed by Army researchers at WRAIR

10.